We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dolutegravir/rilpivirine for the treatment of HIV-1 infection.
- Authors
Dowers, Ellen; Zamora, Francis; Barakat, Lydia Aoun; Ogbuagu, Onyema
- Abstract
Much progress has been made in the development of antiretroviral therapies (ARTs) for HIV-1 infection. Beginning a little over a decade ago, single tablet combination regimens (STRs) became available, and subsequently, newer STR formulations with improved safety profiles have emerged. Recently, there is a growing interest in regimen simplification with the primary goal of further reducing long-term toxicities of ART and improving medication adherence. Dolutegravir/rilpivirine (DTG/RPV) was approved by the US Food and Drug Administration (FDA) as the first dual antiretroviral STR for the maintenance therapy of HIV-1 infection. Following an extensive review of all published papers on RPV and DTG, administered alone and in combination, extracted from databases including PubMed, Google scholar, and EMBASE, as well as drug package inserts and conference abstracts and proceedings, this review discusses the chemical properties and composition, pharmacodynamics and pharmacokinetic properties, clinical trial efficacy and safety data, as well as important drug–drug interactions associated with DTG/RPV. An expert opinion section discusses ideal candidates for DTG/RPV in the context of available but limited data and in comparison to currently available and emerging ART alternatives.
- Subjects
DRUG information materials; INFECTION treatment; DRUG packaging; CLINICAL trials; ART
- Publication
HIV/AIDS - Research & Palliative Care, 2018, Vol 10, p215
- ISSN
1179-1373
- Publication type
Article
- DOI
10.2147/HIV.S157855